secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunityBio, Inc. (IBRX)
CIK:        0001326110
Form:       8-K
Filed at:   2026-04-06T23:59:59+00:00
Accession:  0001193125-26-142932
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmunityBio submits response to FDA OPDP Warning Letter; outlines corrective actions
--------------------------------------------------------------------------------

- Submitted comprehensive response to FDA OPDP Warning Letter dated March 13, 2026.
- Identified podcast removed from corporate website; requested removal from third-party platforms.
- TV advertisement cited in FDA letter was never broadcast or disseminated to the public.
- Implementing enhanced compliance: executive training, expanded PRC protocols, external regulatory counsel.
- CEO Richard Adcock reaffirms commitment to accurate and compliant promotional communications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326110/000119312526142932/0001193125-26-142932-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326110/000119312526142932/d70606d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-142932

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer